Based on targeting COX2 and modulating the Keap1 - Nrf2 and ER stress - related pathways, we preliminarily explored the underlying mechanism of EPT in alleviating early NAFLD progression. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.